Another consideration relies on the presence of an inflammatory microenvironment from the earliest stages of tumour progression, which makes it reasonable to assume that both APOBEC- and ADAR-derived signalling may be simultaneously active in tumour cells. The gene discussed is ADAR; the disease is neoplasm.